Document:

Amended and Restated Investors' Rights Agreement

 Exhibit 4.02 

AMYRIS BIOTECHNOLOGIES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of March 12, 2010, by and
among Amyris Biotechnologies, Inc., a California corporation (the “Company”), and the holders of Series A Preferred Stock listed on Exhibit A attached hereto (the “Series A Preferred Stock”), the Series
B Preferred Stock listed on Exhibit B attached hereto (the “Series B Preferred Stock”), the Series B-1 Preferred Stock listed on Exhibit C attached hereto (the “Series B-1 Preferred Stock”), the Series
C Preferred Stock listed on Exhibit D attached hereto (the “Series C Preferred Stock”), and the Series C-1 Preferred Stock listed on Exhibit E attached hereto (the “Series C-1 Preferred Stock”, and
together with the Series A Preferred Stock, the Series B Preferred Stock, the Series B-1 Preferred Stock, and the Series C Preferred Stock, the “Preferred Stock”) (each, an “Investor” and collectively, the
“Investors”) and the individuals listed on Exhibit F hereto (each, a “Common Holder” and, together, the “Common Holders”). 

RECITALS 

WHEREAS, the Company and certain of the Investors are parties to that certain Amended and Restated Investors’ Rights Agreement made
and entered into as of July 31, 2009, as subsequently amended by Amendment No. 1 thereto (the “Previous Agreement”); 

WHEREAS, concurrently herewith, certain of the Investors and the Company are entering into a Series C-1 Preferred Stock Purchase
Agreement of even date herewith (the “Series C-1 Agreement”), pursuant to which such Investors are purchasing from the Company shares of its Series C-1 Preferred Stock; 

WHEREAS, in order to induce the Company to enter into the Series C-1 Agreement and to induce certain of the Investors to purchase shares
of Series C-1 Preferred Stock pursuant to the Series C-1 Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the
Investors and certain other matters as set forth herein; and 
 WHEREAS, this Agreement has been signed and delivered by the
Company and by the requisite holders as set forth in Section 3.7 of the Previous Agreement. 
 NOW, THEREFORE, THE PARTIES
HEREBY AGREE AS FOLLOWS: 
 1.          Registration Rights. The
Company covenants and agrees as follows: 
 1.1        Definitions. For purposes
of this Section 1: 
 (a)        The term “Act”
means the Securities Act of 1933, as amended. 
 (b)        The term
“Form S-3” means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that 

 
permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(c)        The term “Holder” means any Investor having purchased more than 5%
of the Preferred Stock sold by the Company and, except with respect to Sections 1.2, 1.12, 1.13 and Section 2 hereof, the Common Holders owning or having the right to acquire Registrable Securities or any assignee thereof in accordance
with Section 1.13 hereof. 
 (d)        The term “1934 Act” shall
mean the Securities Exchange Act of 1934, as amended. 
 (e)        The terms
“register,” “registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or
ordering of effectiveness of such registration statement or document. 
 (f)        The
term “Registrable Securities” means: (i) any Common Stock issued or issuable upon conversion of the Preferred Stock of the Company, (ii) other than with respect to Sections 1.2, 1.12, 1.13 and Section 2 hereof,
any Common Stock of the Company held by the Common Holders, (iii) the Common Shares, as defined in that certain Stock Transfer Agreement, dated December 24, 2009, by and among the Company, certain holders of the Company’s Preferred
Stock and certain holders of the Company’s Common Stock, and (iv) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for, or in replacement of, the securities set forth in subsection (i), (ii) or (iii) hereof, excluding, however, any Registrable Securities which (A) have previously been registered or
which have been sold to the public either pursuant to a registration statement or Rule 144, (B) which have been sold in a private transaction in which the transferor’s rights under this Agreement are not assigned, (C) held by a Holder
(together with its affiliates) if, as reflected on the Company’s list of shareholders, such Holder (together with its affiliates) holds less than 1% of the Company’s outstanding Common Stock (treating all shares of Preferred Stock on an as
converted basis) or (D) held by a Holder (together with its affiliates) if the Company has completed its IPO and all shares of Common Stock of the Company issuable or issued upon conversion of the shares held by and issuable to such Holder (and
its affiliates) may be sold pursuant to Rule 144 during a ninety (90) day period. 

(g)        The number of shares of “Registrable Securities then outstanding”
shall mean the number of shares of Common Stock that are Registrable Securities and (i) are then issued and outstanding or (ii) are then issuable pursuant to the exercise or conversion of then outstanding and then exercisable options,
warrants or convertible securities. 
 (h)        The term “SEC” shall
mean the Securities and Exchange Commission. 
 1.2        Request
for Registration. 
 (a) If the Company shall receive at any time after the earlier of (i) three (3) years after
the date hereof and (ii) one-hundred eighty (180) days after the effective 
  

 2 

 
date of the first registration statement for an underwritten public offering of the Company’s Common Stock, a written request from the Holders of at least thirty percent (30%) of the
Registrable Securities then outstanding that the Company use its commercially reasonable efforts to file a registration statement under the Act covering the registration of at least twenty percent (20%) of the Preferred Stock of the Company
having an aggregate offering price to the public of not less than $5,000,000 (net of any underwriters’ discounts or commissions), then the Company shall: 

(i)        within thirty (30) days of the receipt thereof, give written notice of such
request to all Holders; and 
 (ii)        use its commercially reasonable efforts to
effect, as soon as practicable, but no later than ninety (90) days except in connection with the Company’s first registered public offering of its Securities, the registration under the Act of all Registrable Securities that the Holders
request to be registered, subject to the limitations of subsection 1.2(b). 

(b)        If the Holders initiating the registration request hereunder (the “Initiating
Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to subsection 1.2(a) and the Company shall
include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of
any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting
(unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as
provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises
the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten (including Registrable Securities), then the Initiating Holders shall so advise all Holders of Registrable Securities that would
otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders thereof, including the Initiating Holders, in proportion (as nearly as
practicable) to the amount of Registrable Securities of the Company owned by each Holder; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all
securities other than Registrable Securities are first entirely excluded from the underwriting. 

(c)        Notwithstanding the foregoing, if the Company shall furnish to Holders requesting a
registration statement pursuant to this Section 1.2 a certificate signed by the President or Chief Executive Officer of the Company stating that, in the good-faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its shareholders for such registration statement to be filed, the Company shall have the right to defer taking action with respect to such filing for a period not to exceed ninety (90) days after receipt of the
request of the Initiating Holders, provided such right may not be exercised more than once 
  

 3 

 
in any twelve (12) month period. 

(d)        In addition, the Company shall not be obligated to effect, or to take any action to
effect, any registration pursuant to this Section 1.2: 
 (i)        After the
Company has effected two (2) registrations pursuant to this Section 1.2 and such registrations have been declared or ordered effective; 

(ii)        During the period starting with the date ninety (90) days prior to the
Company’s good-faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of the first registration statement for an underwritten public offering of the Company’s Common Stock
(the “IPO”); provided that the Company delivers notice to the Initiating Holders within thirty (30) days of any such registration request and the Company is actively employing in good faith all commercially
reasonable efforts to cause such registration statement to become effective; or 

(iii)        If the Initiating Holders propose to dispose of shares of Registrable Securities
that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.12 below. 

1.3        Company Registration. If (but without any obligation to do so) the Company
proposes to register for its own account, or the account of others, any of its capital stock or other securities under the Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to
the sale of securities to participants in a Company stock plan, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered or an SEC Rule 145 transaction), the Company shall, at such time, promptly give
each Holder written notice of such registration. Upon the written request of each Holder given within thirty (30) days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the provisions
of Section 1.8, use its commercially reasonable efforts to cause to be registered under the Act all of the Registrable Securities that each such Holder has requested to be registered. If a Holder decides not to include all of its Registrable
Securities in any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be
filed by the Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. 

1.4        Obligations of the Company. Whenever required under this Section 1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)        Prepare and file with the SEC a registration statement with respect to such
Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for a 
  

 4 

 
period that is the shorter of one hundred twenty (120) days or until the distribution contemplated in the Registration Statement has been completed; provided, however, that
(i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the
Company; and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, such 120-day period shall be extended, if necessary, to keep the registration
statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act
governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment that (x) includes any prospectus required by Section 10(a)(3) of the Act or (y) reflects facts or events representing a
material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (x) and (y) above to be contained in periodic reports filed pursuant to
Section 13 or 15(d) of the 1934 Act in the registration statement. 

(b)        Prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement. 

(c)        Furnish to the Holders such numbers of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d)        Use its commercially reasonable efforts to register and qualify the securities
covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, except as may be required by the Act. 

(e)        In the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement.

 (f)        Notify each Holder of Registrable Securities covered by such registration
statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing. The Company will use its commercially reasonable
efforts to amend or supplement such prospectus to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading
in light 
  

 5 

 
of the circumstances then existing. 

(g)        Cause all such Registrable Securities registered hereunder to be listed on a national
exchange or trading system and each securities exchange on which similar securities issued by the Company are then listed. 

(h)        Provide a transfer agent and registrar for all Registrable Securities registered
pursuant hereto and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

(i)        Furnish, at the request of any Holder requesting registration of Registrable
Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through
underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, an opinion, dated such date, of the counsel representing the Company for the
purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities. 

(j)        Furnish on the date that such Registrable Securities are delivered to the
underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration
statement with respect to such securities becomes effective a letter, dated as of such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants
to underwriters in an underwritten public offering addressed to the underwriters. 

1.5        Furnish Information. It shall be a condition precedent to the obligations of
the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it,
and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities. 

1.6        Expenses of Demand Registration. All expenses (other than underwriting
discounts and commissions) incurred in connection with registrations, filings or qualifications pursuant to Section 1.2, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, and
fees and expenses of counsel to the Company and one (1) counsel to the Holders (such expenses of counsel to the Holders shall not exceed $25,000) shall be borne by the Company; provided, however, that the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in
which case all participating Holders shall bear such expenses), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2 (in which event such right shall be
forfeited by all Holders); provided, further, however, that if at the time of such withdrawal, the Holders have 

 

 6 

 
learned of material adverse information or a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have
withdrawn the request based upon such information with reasonable promptness following disclosure by the Company of such material adverse information or material adverse change, then the Holders shall not be required to pay any of such expenses and
shall retain their rights pursuant to Section 1.2. 
 1.7        Expenses of
Company Registration. The Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to the registrations pursuant to Section 1.3 for each Holder
(which right may be assigned as provided in Section 1.13), including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, and fees and expenses of counsel to the Company and one
(1) counsel to the Holders (such expenses of counsel to the Holders shall not exceed $25,000), but excluding underwriting discounts and commissions relating to Registrable Securities. 

1.8        Underwriting Requirements. If a registration statement for which the Company
gives notice pursuant to Section 1.3 is for an underwritten offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any Holder’s Registrable Securities to be included in a registration
pursuant to Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to
distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Agreement, if
the managing underwriter(s) determine(s) in good faith that marketing factors require a limitation of the number of shares to be underwritten, then the managing underwriter(s) may exclude shares (including Registrable Securities) from the
registration and the underwriting, and the number of shares that may be included in the registration and the underwriting shall be allocated first, to the Company, second, to each of the Holders (other than any Holder who is also a
Common Holder) requesting inclusion of their Registrable Securities in such registration statement on a pro rata basis based upon the total number of Registrable Securities then held by each such Holder, third, to each Holder who is also a
Common Holder requesting inclusion of his Registrable Securities in such registration statement on a pro rata basis based upon the total number of Registrable Securities then held by each Holder who is also a Common Holder, and fourth, to any
other securityholder; provided, however, that the right of the underwriters to exclude shares (including Registrable Securities) from the registration and underwriting as described above in this Section 1.8 shall be restricted so
that: (i) the number of Registrable Securities then held by the Investors included in any such registration is not reduced below twenty-five percent (25%) of all the shares included in the registration, except for a registration relating
to the Company’s initial public offering of its Common Stock, from which all Registrable Securities may be excluded and (ii) all shares held by securityholders that are not Registrable Securities shall first be excluded from such
registration and underwriting before any Registrable Securities are so excluded, unless holders of two-thirds (2/3) of the Registrable Securities then outstanding approve the inclusion of such shares held by securityholders that are not
Registrable Securities. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least twenty (20) business days prior to

  

 7 

 
the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder
that is a venture capital fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners and shareholders of such Holder, or the estates and family members of any such partners, shareholders and retired partners
and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying
registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence. 

1.9          Delay of Registration. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.10        Indemnification. In the event any Registrable Securities are included in a
registration statement under this Section 1: 
 (a)        To the extent permitted
by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Act) for such Holder, the partners, members, officers and directors of such Holder and each person, if any, who controls such Holder or underwriter
within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a “Violation”) by the Company: (i) any untrue statement or alleged untrue
statement of a material fact contained in such registration statement or incorporated by reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission
or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state
securities law or any rule or regulation promulgated under the Act, the 1934 Act or any state securities law; and the Company will pay to each such Holder, the partners, members, officers and directors of such Holder, underwriter or controlling
person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in
this subsection 1.10(a) shall not apply (i) to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably
withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by any such Holder, the partners, members, officers and directors of such Holder, underwriter or controlling person, (ii) if such untrue statement (or alleged untrue
statement) or omission (or alleged omission) was contained in a preliminary prospectus and corrected in a final or amended prospectus or supplement thereto, copies of which were delivered to such Holder on a timely basis, and such Holder failed to
deliver a copy of the final or amended prospectus at or prior to the confirmation for the sale of the Registrable 
  

 8 

 
Securities to the persons asserting any such loss, claim, damage, or liability in any case where such delivery is required by the Securities Act, or (iii) to the extent that the loss, claim,
damage or liability as to which indemnification is sought is in connection with an offer or sale made by such Holder in breach of the terms of this Agreement. 

(b)        To the extent permitted by law, each selling Holder will indemnify and hold harmless
the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other Holder selling securities in such
registration statement and any partners, members, officers and directors of such Holder and any controlling person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the
foregoing persons may become subject, under the Act, the 1934 Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the
extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay, as incurred, any
legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this subsection 1.10(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided,
however, that the indemnity agreement contained in this subsection 1.10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the
Holder, which consent shall not be unreasonably withheld; provided that in no event shall any indemnity under this subsection 1.10(b) exceed the net proceeds from the offering received by such Holder. 

(c)        Promptly after receipt by an indemnified party under this Section 1.10 of notice
of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.10, deliver to the indemnifying party a written
notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof
with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one
separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to the
indemnifying party’s ability to defend such action, shall relieve such indemnifying party of liability to the indemnified party under this Section 1.10 to the extent of such prejudice, but the omission to deliver written notice to the
indemnifying party will not relieve the indemnifying party of any liability that it may have to any indemnified party otherwise than under this Section 1.10. 

(d)        If the indemnification provided for in this Section 1.10 is held by a court of
competent jurisdiction to be unavailable to an indemnified party with respect to any loss, 
  

 9 

 
liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by
such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection
with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by
a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and
the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, however, that in no event shall any contribution by a Holder hereunder, when taken together
with any indemnification by such Holder pursuant to Section 1.10(b), exceed the net proceeds from the offering received by such Holder. 

(e)        Notwithstanding the foregoing, to the extent that the provisions on indemnification
and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control; provided,
however, that to the extent the underwriting agreement does not address a matter addressed by this Agreement, the failure to address such matter shall not be deemed a conflict between the provisions of this Agreement and the underwriting
agreement. 
 (f)        The obligations of the Company and Holders under this
Section 1.10 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 

1.11        Reports Under the 1934 Act. With a view to making available to the Holders
the benefits of Rule 144 promulgated under the Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on
Form S-3, the Company agrees to use all commercially reasonable efforts to: 

(a)        make and keep public information available, as those terms are understood and defined
in SEC Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public; 

(b)        take such action, including the voluntary registration of its Common Stock under
Section 12 of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities; 

(c)        file with the SEC in a timely manner all reports and other documents required of the
Company under the Act and the 1934 Act; and 
 (d)        furnish to any Holder, so
long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the

  

 10 

 
effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies
as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents filed under the 1934 Act
by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form.

 1.12        Form S-3 Registration. If the Company shall receive from any
Holder or Holders a written request or requests that the Company effect a registration on Form S-3 or any similar short-form registration statement and any related qualification or compliance with respect to all or a part of the Registrable
Securities owned by such Holder or Holders, the Company will: 
 (a)        promptly
give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and 

(b)        use its commercially reasonable efforts to effect, as soon as practicable, such
registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such
request, together with all or such portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the
Company; provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.12: (i) if Form S-3 is not available for such offering by the
Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the
public (net of any underwriters’ discounts or commissions) of less than two million dollars ($2,000,000); (iii) if the Company shall furnish to the Holders a certificate signed by the President or Chief Executive Officer of the Company
stating that, in the good-faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its shareholders for such Form S-3 registration to be effected at such time, in which event the Company
shall have the right to defer the filing of the Form S-3 registration statement for a period not to exceed ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.12 provided that such right may
not be exercised more than once in any twelve (12) month period; (iv) if the Company has, within the twelve (12) month period preceding the date of such request, already effected one (1) registration on Form S-3 for the
Holders pursuant to this Section 1.12; or (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration,
qualification or compliance. 
 Subject to the foregoing, the Company shall file a registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. All expenses incurred in connection with registrations requested pursuant to this
Section 1.12, including (without limitation) all registration, filing, qualification, printers’ and accounting fees and the fees and expenses of counsel to the Company and fees and expenses of counsel to the Holders, but excluding any

  

 11 

 
underwriters’ discounts or commissions, associated with Registrable Securities, shall be borne pro rata by the participating Holders. Registrations effected pursuant to this
Section 1.12 shall not be counted as demands for registration or registrations effected pursuant to Section 1.2 or Section 1.3. 

The Company shall not be obligated to effect any registration pursuant to this Section 1.12 if the Company delivers to the Holders
requesting registration under this Section 1.12 an opinion, in form and substance reasonably acceptable to such Holders, of counsel reasonably satisfactory to such Holders, that all Registrable Securities so requested to be registered may be
sold or transferred pursuant to Rule 144 under the Act. 

1.13        Assignment of Registration Rights. The rights to cause the Company to
register Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities provided: (a) the Company is, within a reasonable time after such
transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound
by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section 1.14 below; (c) the transfer involves a transfer of at least one percent (1%) of then outstanding shares of
Registrable Securities (as adjusted for dividends, splits, recapitalizations and the like); provided, however, that transfers or assignments to partners, limited partners, retired partners, members, former members, shareholders,
parents, children, spouses, trusts or affiliates of a Holder shall be without restriction as to the minimum number of shares to be transferred; and (d) such assignment shall be effective only if immediately following such transfer the further
disposition of such securities by the transferee or assignee is restricted under the Act. 

1.14        “Market Stand-Off” Agreement. Each Holder hereby agrees that,
during the period of duration specified by the Company and an underwriter of common stock or other securities of the Company, following the effective date of a registration statement of the Company filed under the Act pertaining to the IPO, it shall
not, to the extent requested by the Company or such underwriter, directly or indirectly sell, offer to sell, contract to sell (including, without limitation, any short sale), grant any option to purchase or otherwise transfer or dispose of (other
than to donees who agree to be similarly bound) any securities of the Company held by it at any time during such period except common stock included in such registration; provided, however, that: 

(a)        such agreement shall be applicable only to the first such registration statement of
the Company pertaining to the IPO; 
 (b)        all executive officers, directors and
holders of one percent (1%) or more of the outstanding common stock (on an as converted to common stock basis) of the Company enter into similar agreements or arrangements; 

(c)        such agreement shall provide that any discretionary releases (other than
discretionary financial hardship waivers not exceeding $25,000 for any holder) from the lock-up be allocated to holders of Registrable Securities on a pro rata basis; and 
  

 12 

 (d)        such market stand-off time period shall
not exceed one hundred eighty (180) days; provided, however, that, if during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or
prior to the expiration of the restricted period the Company announces that it will release earnings results during the 16-day period beginning on the last day of the restricted period, and if the Company’s securities are listed on the Nasdaq
Stock Market and Rule 2711 of thereof applies, then the restrictions imposed by this Section 1.14 shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of
the material news or material event. 
 In order to enforce the foregoing covenant, the Company may impose stop-transfer
instructions with respect to the Registrable Securities of each Investor (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. 

Notwithstanding the foregoing, the obligations described in this Section 1.14 shall not apply to a registration relating solely to
employee benefit plans on Form S-4 or Form S-8 or similar forms that may be promulgated in the future, or to a registration relating solely to an SEC Rule 145 transaction. 

1.15        Termination of Registration Rights. No Holder shall be entitled to exercise
any right provided for in this Section 1 after five (5) years following the consummation of the IPO. 

2.             Covenants of the Company. 

2.1           Delivery of Financial Statements. The Company shall deliver to
each Investor, for so long as such Investor holds (together with its affiliates) at least 5% of the Registrable Securities or 39,589 shares of Series B-1 Preferred (each as adjusted for dividends, splits, recapitalizations and the like) (each, a
“Significant Investor”): 
 (a)        as soon as practicable, but in
any event within forty-five (45) days after the end of each fiscal year of the Company, the Company’s annual operating plan, an income statement for such fiscal year, a balance sheet of the Company as of the end of such year, a statement
of shareholder’s equity as of the end of such year and a statement of cash flows for such fiscal year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (except that
such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with generally accepted accounting principles), and such financial statements will
be accompanied by a report and opinion thereon by independent public accountants selected by the Company’s Board of Directors within one hundred twenty (120) days after the end of each fiscal year; 

(b)        as soon as practicable but in no event more than forty-five (45) days after the
end of each of the first three quarters of each fiscal year of the Company, an unaudited income statement, balance sheet and statement of cash flows for and as of the end of each such quarter, such unaudited financial statements to be in reasonable
detail; and 
 (c)        as soon as practicable after the end of each month, and in
any event 
  

 13 

 
within thirty (30) days after the end of each month, an unaudited consolidated balance sheet of the Company as of the end of such monthly period, and unaudited consolidated statements of
income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with generally accepted accounting principles. 

2.2        Inspection Rights. The Company will maintain true books and records of account
in which full and correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted
therein, and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied. The Company shall permit each Significant Investor, at such Significant
Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all upon reasonable notice and at such
reasonable times as may be requested by such Significant Investor; provided, however, that the Company shall not be obligated under this Section 2.2 to provide information that it deems in good faith to be a trade secret or
similar confidential or proprietary information if it believes in good faith that such disclosure would be detrimental to the Company. The rights set forth in this Section 2.2 shall be exercised solely in furtherance of the proper interests of
such Significant Shareholder as an investor in the Company, and any Significant Shareholder exercising its rights of inspection hereunder agrees to maintain the confidentiality of all financial and other confidential information of the Company
disclosed to it. At the request of the Company, each Significant Shareholder shall, as a condition of the exercise of its rights of inspection thereunder, execute a confidentiality agreement with the Company in form and substance satisfactory to the
Company. 
 2.3        Option/Common Stock Vesting. 

(a)        Unless otherwise unanimously approved by the Board of Directors or as otherwise
contemplated herein, the Company hereby covenants that all stock, stock equivalents and options issued after the date hereof to employees, directors, consultants and other service providers of the Company shall vest in accordance with the following
vesting schedule: twenty (20%) of the shares to vest at the expiration of one (1) year from (i) the date of the grant if the grantee is then in the service of the Company or (ii) the date service commences if the grantee is not
then in service of the Company, and the remaining eighty percent (80%) of the shares to vest in a series of forty-eight (48) successive and equal monthly installments thereafter upon the completion by the employee, director, consultant or
service provider of each month of service to the Company. Unless otherwise unanimously approved by the Board of Directors, the Company’s repurchase option shall provide that upon termination of the service of the employee, director, consultant
or other service provider, with or without cause, the Company or its assignee (to the extent permissible under applicable securities laws) retains the option to repurchase at cost any unvested shares held by such shareholder. 

(b)        The shares of Common Stock held by Jay D. Keasling shall accelerate in full in the
event there is a Change of Control of the Company (as defined in the applicable stock restriction agreement) followed by a termination of such person’s services to the Company without cause. 

 

 14 

 2.4        Right of First Offer. Subject to
applicable securities laws and the terms and conditions specified in this Section 2.4, the Company hereby grants to each Significant Investor and to each Investor for so long as such Investor holds (together with its affiliates) at least
401,284 shares of Series C Preferred Stock and/or Series C-1 Preferred Stock (as adjusted for dividends, splits, recapitalizations and the like) (together with the Significant Investors, the “First Offer Rights Holders”) a right of
first offer with respect to future sales by the Company of its Shares (as hereinafter defined). A First Offer Rights Holder shall be entitled to apportion the right of first offer hereby granted it among itself and its partners and affiliates in
such proportions as it deems appropriate. Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, any class or series of its capital stock (“Shares”),
the Company shall first make an offering of such Shares to each First Offer Rights Holder in accordance with the following provisions: 

(a)        The Company shall deliver a notice by certified mail (“Notice”) to
the First Offer Rights Holders stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such Shares. 

(b)        Within ten (10) business days after giving of the Notice, each First Offer
Rights Holder may elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of common stock issued and held, or issuable upon conversion
of the Registrable Securities then held, by such First Offer Rights Holder bears to the total number of shares of common stock of the Company then outstanding (assuming full conversion and exercise of all then outstanding convertible and exercisable
securities of the Company). The Company shall promptly, in writing, inform each First Offer Rights Holder that elects to purchase all the shares available to it (“Fully Exercising Investor”) of any other First Offer Rights
Holder’s failure to do likewise. During the five (5) business day period commencing after such information is given, each Fully Exercising Investor shall be entitled to elect to purchase up to that portion of the Shares not subscribed for
by the First Offer Rights Holders that is equal to the proportion that the number of shares of common stock issued and held, or issuable upon conversion of Registrable Securities then held, by such Fully Exercising Investor bears to the total number
of shares of common stock issued and held, or issuable upon conversion of the Registrable Securities then held, by all Fully Exercising Investors who wish to purchase some of the unsubscribed shares. 

(c)        If all Shares that First Offer Rights Holders are entitled to obtain pursuant to
subsection 2.4(b) are not elected to be purchased as provided in subsection 2.4(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period provided in subsection 2.4(b) hereof, offer the
remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Notice. If the Company does not consummate the sale of the Shares within
such period, or if such agreement is not consummated within forty-five (45) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the First Offer
Rights Holders in accordance herewith. 
 (d)        The right of first offer in this
Section 2.4 shall not be applicable to 
  

 15 

 
issuances of securities of the Company that are not “Additional Stock” (as defined in Article III, Section B(4)(d)(i) of the Company’s Amended and Restated Articles of
Incorporation, as such Amended and Restated Articles of Incorporation may be amended from time to time). 

(e)        The right of first offer set forth in this Section 2.4 may not be assigned or
transferred, except that (i) such right is assignable by each First Offer Rights Holder to any wholly owned subsidiary or parent of, or to any corporation or entity that is, within the meaning of the Act, controlling, controlled by or under
common control with, any such First Offer Rights Holder and (ii) such right is assignable between and among any of the First Offer Rights Holders or between and among any such First Offer Rights Holder and any affiliated partnerships, venture
capital funds or other entities of such First Offer Rights Holder. 

2.5        Proprietary Information Agreements. The Company shall require each employee
hired by the Company to execute a proprietary information and inventions agreement and each consultant or contractor engaged by the Company to execute a consulting agreement, each in a form as recommended by the Company’s legal counsel.

 2.6        Assignment of Information and Inspection Rights. The information
rights set forth in Section 2.1 and inspection rights in Section 2.2 may be assigned (but only with all related obligations) by a Significant Investor to a transferee or assignee of such securities that (a) is a subsidiary, parent,
general partner, limited partner, retired partner, member or retired member or stockholder of a Significant Investor that is a corporation, partnership or limited liability company or an entity affiliated by common control (or other related entity)
with such Significant Investor or (b) is a Significant Investor’s family member or trust for the benefit of an individual Holder or (c) qualifies as a Significant Investor after such assignment or transfer. 

2.7        Right of First Refusal. Any shares of Common Stock of the Company issued after
the date hereof (other than shares of Common Stock issued upon conversion of Preferred Stock) shall be subject to a right of first refusal in favor of the Company upon transfer. 

2.8        Assignment of Right of First Refusal. In the event the Company elects not to
exercise any right of first refusal or right of first offer the Company may have on a proposed transfer of any of the Company’s outstanding capital stock pursuant to the Company’s charter documents, by contract or otherwise, the Company
shall, to the extent it may do so, assign such right of first refusal or right of first offer to each Significant Investor. In the event of such assignment, each Significant Investor shall have a right to purchase its pro rata portion of the capital
stock proposed to be transferred. Each Significant Investor’s pro rata portion shall be equal to the product obtained by multiplying (i) the aggregate number of shares proposed to be transferred by (ii) a fraction, the numerator of
which is the number of shares of Registrable Securities held by such Significant Investor at the time of the proposed transfer and the denominator of which is the total number of Registrable Securities owned by all Significant Investors at the time
of such proposed transfer. 
 2.9        Insurance. The Company shall continue
to bind and maintain director & officer insurance with a carrier or carriers and on such terms and in such amount as is satisfactory to the Board, unless the Board determines that procuring such insurance would not be in the best interest
of the Company and its stockholders. 
  

 16 

 2.10        Key Man Insurance. As soon as
practicable after the Initial Closing, the Company will bind and maintain a key-man life insurance policy on the life of John G. Melo with a carrier or carriers and on such terms and in such amount as is satisfactory to the Board, unless the Board
determines that procuring such insurance would not be in the best interest of the Company and its stockholders. 

2.11        Director Indemnification. The Company will use its best efforts to maintain
indemnification agreements with directors that will indemnify board members to the broadest extent permitted by applicable law. In the event the Company merges with another entity and is not the surviving corporation, or transfers all of its assets,
proper provisions shall be made so that successors of the Company assume the Company’s obligations with respect to the indemnification of directors. 

2.12        Amended and Restated Right of First Refusal and Co-Sale Agreement. The
Company shall use commercially reasonable efforts to cause all officers and holders of at least 5% of the Company’s Common Stock to become a party to the Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of the date
hereof. 
 2.13        Amended and Restated Voting Agreement. The Company shall
use commercially reasonable efforts to cause all officers and holders of at least 1% of the Company’s Common Stock to become a party to the Amended and Restated Voting Agreement, dated as of the date hereof. 

2.14        Reservation of Common Stock. The Company will at all times reserve and
keep available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 

2.15        Termination of Covenants. The covenants set forth in Section 2 hereof
shall terminate as to Investors and be of no further force or effect upon (i) the consummation of a firm commitment underwritten public offering of the Company’s securities pursuant to which all outstanding shares of Preferred Stock
automatically convert into Common Stock, (ii) a Liquidation Event (as defined in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time) or (iii) with respect to Sections 2.1 and 2.2, when the
Company first becomes subject to the periodic reporting requirements of Section 12(g) or Section 15(d) of the 1934 Act, whichever event shall first occur. 

3.          Miscellaneous. 

3.1        Successors and Assigns. Except as otherwise provided herein, the terms and
conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 3.2        Governing Law. This Agreement shall be governed by and construed
under the laws of the State of California without regard for conflicts of laws principles. 
  

 17 

 3.3        Counterparts. This Agreement may
be executed in two or more counterparts, including counterparts transmitted by facsimile, other electronic transmission or otherwise, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 3.4        Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

3.5        Notices. All notices required or permitted under this Agreement shall be given
in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the
next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the signature page hereof, or at such other
address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with
written verification of receipt. 
 3.6        Attorneys’ Fees. If any
dispute among the parties to this Agreement results in litigation, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with
respect to this Agreement, including, without limitation, such reasonable fees and expenses of attorneys and accountants, that shall include, without limitation, all fees, costs and expenses of appeals. 

3.7        Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of a majority of the Registrable Securities
then outstanding, provided that such amendment does not disproportionately impact any Holders; provided, however, that any Registrable Securities that are held by the Common Holders shall only be taken into account for the
purposes of the foregoing sentence in the event that an amendment or waiver of any term of this Agreement would materially and adversely affect the rights of the Common Holders hereunder; provided further, that any amendment of a provision
relating to the termination of any rights of the Investors shall require a majority of the then-effected Investors. Notwithstanding the above, Sections 2.1, 2.2 and 2.4 may be amended and the observance of any terms in such sections may be waived
(either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority in interest of the First Offer Rights Holders based on the number of shares of
Registrable Securities then held by the First Offer Rights Holders; provided, further, that for any amendment or waiver of any provision herein that would have a material, adverse and disproportionate effect on a series of Preferred
Stock relative to any other series of Preferred Stock, consent of the holders of at least the majority of such series of Preferred Stock voting as a separate class shall be required. Any amendment or waiver effected in accordance with this paragraph
shall be binding upon each holder of any Registrable Securities then outstanding, each future holder of all such Registrable Securities and the Company. 
  

 18 

 3.8        Severability. If any of the
provisions of this Agreement should, for any reason, be held by a court or other tribunal of competent jurisdiction to be illegal, invalid or unenforceable in any respect, such provisions shall be limited or eliminated to the minimum extent
necessary so that this Agreement shall otherwise remain in full force and effect. 

3.9        Aggregation of Stock. All shares of Registrable Securities held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

3.10        Entire Agreement. This Agreement and the Exhibits hereto, along with the
Series B Agreement and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof and no party shall be liable or bound to any other
in any manner by any oral or written representations, warranties, covenants or agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written
representations, warranties, covenants or agreements outside of this Agreement. 

3.11        Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach,
default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of
any breach, default or noncompliance under the Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative. 

3.12        Additional Investors. Notwithstanding anything to the contrary contained
herein, if the Company shall issue additional shares of its Preferred Stock, any purchaser of such shares of Preferred Stock shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement and shall be deemed, as applicable, an “Investor” or a “Holder,” and a party hereunder. 

3.13        Previous Agreement. The Previous Agreement is hereby amended and superseded
in its entirety and restated herein. Such amendment and restatement is effective upon execution and delivery of this Agreement by the Company and by the requisite holders as set forth in Section 3.7 of the Previous Agreement. Upon such
execution, all provisions of, rights granted and covenants made in the Previous Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect. 

[Signature Pages Follow] 
  

 19 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	COMPANY:
	
	AMYRIS BIOTECHNOLOGIES, INC.
		
	By:	 	/s/ John G. Melo
		 	John G. Melo
		 	Chief Executive Officer 

			
		
	Address:	 	 5885 Hollis Street, Ste. 100

Emeryville, CA 94608

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	COMMON HOLDERS:	 	
		
	/s/ Jack D. Newman	 	 
	Jack D. Newman	 	

			
		
	Address:  	 	 
		
		 	 

			
		
	/s/ K. Kinkead Reiling	 	 
	K. Kinkead Reiling	 	

			
		
	Address:  	 	 
		
		 	 

			
		
	  	 	 
	Jay D. Keasling	 	

			
		
	Address:  	 	 
		
		 	 

			
		
	/s/ Neil Renninger	 	 
	Neil Renninger	 	

			
		
	Address:  	 	 
		
		 	 

 AMENDED AND RESTATED INVESTORS’ RIGHTS
AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	COMMON HOLDER:	 	
		
	/s/ John G. Melo	 	 
	John G. Melo	 	

			
		
	Address:  	 	 
		
		 	 

  

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTORS:
	
	DAG Ventures III-QP, L.P.
		
	By:	 	DAG Ventures Management III, LLC, its General Partner
		
	By:	 	/s/ Thomas Goodrich
		 	R. Thomas Goodrich, Managing Director

			
	Address:	 	 251 Lytton Ave., Suite 200

Palo Alto, CA 94301

  

			
	DAG Ventures III, L.P.
		
	By:	 	DAG Ventures Management III, LLC, its General Partner
		
	By:	 	/s/ Thomas Goodrich
		 	R. Thomas Goodrich, Managing Director

			
	Address:	 	 251 Lytton Ave., Suite 200

Palo Alto, CA 94301

  

			
	DAG Ventures GP Fund III, LLC
		
	By:	 	DAG Ventures Management III, LLC, its Managing Member
		
	By:	 	/s/ Thomas Goodrich
		 	R. Thomas Goodrich, Managing Director

			
	Address:	 	 251 Lytton Ave., Suite 200

Palo Alto, CA 94301

  

			
	DAG Ventures I-N, LLC
		
	By:	 	DAG Ventures Management, LLC, its Managing Member
		
	By:	 	/s/ Thomas Goodrich
		 	R. Thomas Goodrich, Managing Director

			
	Address:	 	 251 Lytton Ave., Suite 200

Palo Alto, CA 94301

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTORS:
	
	KHOSLA VENTURES III, L.P.
		
	By:	 	/s/ Samir Kaul
	 Name: Samir Kaul

Title: Partner

			
	Address:	 	3000 Sand Hill Road, Bldg. 3, Ste. 170 Menlo Park, CA 94025

			
	
	TPG BIOTECHNOLOGY PARTNERS II, L.P.
		
	By:	 	TPG Biotechnology Genpar II, L.P.
	By:	 	TPG Biotech Advisors II, LLC
		
	By:	 	/s/ Jeffery D. Ekberg
	 Name: Jeffery D. Ekberg

Title: Vice President

			
	Address:	 	 301 Commerce Street, Suite 3300

Fort Worth, Texas 76102

			
	
	KPCB HOLDINGS, INC., AS NOMINEE
		
	By:	 	/s/ John Doerr
	 Name: John Doerr

Title: Partner

			
	Address:	 	 2750 Sand Hill Road
 Menlo
Park, CA 94025

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	NAXOS CAPITAL PARTNERS
		
	By:	 	 

			
	Name:	 	 

			
	Title:	 	 

			
	Address:	 	 

 AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 
 SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	GROBER BUSINESS CORP
		
	By:	 	 

			
	Name:	 	 

			
	Title:	 	 

			
	Address:	 	 Engenho São João, s/no

Várzea, Recife - PE
 Brasil

CEP – 50.741-520

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first above written. 
  

			
	INVESTOR:
	
	MAXWELL (MAURITIUS) LTE LTD
		
	By:	 	/s/ Fidah Alsagoff

			
	Name:	 	Fidah Alsagoff

			
	Title:	 	Authorized Signatory

			
	Address:	 	c/o 60B Orchard Road
		 	#06-18 Tower 2
		 	The Atrium @ Orchard
		 	Singapore 238891
		 	Singapore

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 IN WITNESS WHEREOF, the undersigned has duly executed this Amended and Restated
Investors’ Rights Agreement as of the date set forth below. 
  

							
	Date:______________	 		 	INVESTOR:
			
		 		 	 
		 		 	[Please print exact name of Investor as it should appear on stock certificate.]
				
		 		 	By:	 	 
				
		 		 	Name:	 	 
				
		 		 	Title:	 	 
		 		 	[Please include title if Investor is an entity.]
				
		 		 	Address:	 	 
				
		 		 		 	 
				
		 		 		 	

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

SIGNATURE PAGE 

 EXHIBIT A 

SCHEDULE OF SERIES A INVESTORS 
  

			
	 SERIES A INVESTOR

	 	NUMBER 
OF
SHARES OF SERIES
A STOCK
		
	 Khosla Ventures II, L.P.
	 	3,449,861
		
	 KPCB Holdings, Inc., as nominee
	 	3,449,861
		
	 TPG Biotechnology Partners II, L.P.
	 	2,299,907
		
	 Total
	 	9,199,629

 EXHIBIT B 

SCHEDULE OF SERIES B INVESTORS 
  

			
	 SERIES B INVESTOR

	 	NUMBER OF
 
 SHARES OF SERIES  
B STOCK
		
	 DAG Ventures III, L.P.
	 	44,883            
		
	 DAG Ventures III-QP, L.P.
	 	477,134            
		
	 DAG Ventures GP Fund III, LLC
	 	491            
		
	 DAG Ventures I-N, LLC
	 	281,351            
		
	 Khosla Ventures II, L.P.
	 	150,723            
		
	 KPCB Holdings, Inc., as nominee
	 	150,723            
		
	 TPG Biotechnology Partners II, L.P.
	 	401,929            
		
	 ES East Associates, LLC
	 	9,859            
		
	 BB Trust Dated 2/21/03 (Richard Rock, Trustee)
	 	70,338            
		
	 Crystalsesv Comércio E Representação Ltda.
	 	40,193            
		
	 Santelisa Vale Bioenergia S.A.
	 	40,193            
		
	 Total
	 	1,667,817            

 EXHIBIT C 

SCHEDULE OF SERIES B-1 INVESTORS 
  

			
	 SERIES B-1 INVESTOR

	 	NUMBER OF
 
 SHARES OF SERIES  
B-1 STOCK
		
	 AEI 2008 CleanTech Investments I, LLC
	 	134,639        
		
	 AEI 2008 CleanTech Investments II, LLC
	 	180,127        
		
	 Advanced Equities Amyris Investments I, LLC
	 	226,465        
		
	 Advanced Equities Amyris Investments II, LLC
	 	661,403        
		
	 Advanced Equities Amyris Investments III, LLC
	 	32,258        
		
	 Advanced Equities Amyris Investments IV, LLC
	 	66,240        
		
	 Ameri Private Equity IV, LLC
	 	80,563        
		
	 Aspire Business LTD
	 	98,970        
		
	 Christopher Lenzo
	 	118,765        
		
	 Counter Point Venture Fund II, LP
	 	19,800        
		
	 Erasmus Louisiana Growth Fund II, LP
	 	39,589        
		
	 Exccess Venture Fund I, LLC
	 	79,178        
		
	 Gaenger Family Living Trust of 1995
	 	395        
		
	 GB Sears Family Trust
	 	3,365        
		
	 HS Partners Holdings III, LP
	 	158,353        
		
	 Innovative Financial Private Equity Fund II, LLC
	 	45,527        
		
	 Invest Biotech, LLC
	 	51,275        
		
	 James A. Goddard
	 	989        
		
	 Lit Tele, LLC
	 	395,883        
		
	 Millenium Trust Company
	 	39,589        
		
	 Northport Investments, LLC
	 	53,852        
		
	 TCM2, LLC
	 	39,589        
		
	 Technology Ventures, LLC
	 	39,588        
		
	 The Barlow Family Trust
	 	989        
		
	 Third Amended and Restated Robbins Trust of 1986
	 	4,159        
		
	 Toronto Angel Group Amyris Holdings LP
	 	43,991        
		
	 Total
	 	2,615,721        

 EXHIBIT D 

SCHEDULE OF SERIES C INVESTORS 
  

			
	 SERIES C INVESTOR

	 	NUMBER OF
  SHARES OF 
SERIES  
C STOCK
		
	 Khosla Ventures III, L.P.
	 	321,027            
		
	 KPCB Holdings, Inc., as nominee
	 	321,027            
		
	 TPG Biotechnology Partners II, L.P.
	 	321,027            
		
	 Lit Tele, LLC
	 	802,568            
		
	 DAG Ventures II, L.P.
	 	146,582            
		
	 DAG Ventures III-QP, L.P.
	 	13,788            
		
	 DAG Ventures GP Fund III, LLC
	 	144            
		
	 DAG Ventures I-N, LLC
	 	60,193            
		
	 Grober Business Corp.
	 	802,568            
		
	 Amyris SA (an affiliate of NAXOS Capital Partners)
	 	561,797            
		
	 Advanced Equities Amyris Investments I, LLC
	 	22,685            
		
	 Advanced Equities Amyris Investments II, LLC
	 	65,672            
		
	 Advanced Equities Amyris Investments III, LLC
	 	2,184            
		
	 Advanced Equities Amyris Investments IV, LLC
	 	3,249            
		
	 AEI 2008 CleanTech Investments I, LLC
	 	5,003            
		
	 AEI 2008 CleanTech Investments II, LLC
	 	14,483            
		
	 Third Amended and Restated Robbins Trust of 1986 (Richard K. Robbins, Trustee)
	 	1,213            
		
	 James A. Goddard
	 	288            
		
	 Invest Biotech, LLC
	 	2,648            
		
	 Kevin Kaster
	 	1,271            
		
	 Millenium Trust Company LLP Cust FBO WNA Private Equity Fund B - Amyris LLC
	 	7,945            
		
	 Northern Rivers Silicon Valley Access Fund LP
	 	8,025            
		
	 Michael P. Waldbillig and Louise A. Waldbillig Trust, dated September 16, 2008
	 	1,324            
		
	 Advanced Equities Amyris Investments I, LLC
	 	10,139            
		
	 Advanced Equities Amyris Investments II, LLC
	 	30,724            

 EXHIBIT D 

SCHEDULE OF SERIES C INVESTORS (cont.) 
  

			
	 SERIES C INVESTOR

	 	NUMBER OF
  SHARES OF 
SERIES  
C STOCK
		
	 Advanced Equities Amyris Investments III, LLC
	 	312            
		
	 Advanced Equities Amyris Investments IV, LLC
	 	3,593            
		
	 AEI 2008 CleanTech Investments I, LLC
	 	2,644            
		
	 AEI 2008 CleanTech Investments II, LLC
	 	3,818            
		
	 Northport Investments LLC
	 	3,815            
		
	 Innovative Financial Private Equity
	 	19,662            
		
	 Orgone Capital IV, LLC
	 	61,810            
		
	 HS Partners Holdings III, LP
	 	80,256            
		
	 Phyllis Gardner
	 	264            
		
	 Jeffrey and Andrea Tobias
	 	1,002            
		
	 BCP Investment, L.P.
	 	128,410            
		
	 Richard C. Blum Rollover IRA
	 	240,770            
		
	 Magoo 1, LLC
	 	6,621            
		
	 Advanced Equities Amyris Investments I, LLC
	 	394            
		
	 Advanced Equities Amyris Investments II, LLC
	 	1,249            
		
	 Advanced Equities Amyris Investments III, LLC
	 	96            
		
	 Advanced Equities Amyris Investments IV, LLC
	 	104            
		
	 AEI 2008 CleanTech Investments I, LLC
	 	491            
		
	 AEI 2008 CleanTech Investments II, LLC
	 	812            
		
	 Orgone Capital IV, LLC
	 	12,199            
		
	 Excess Venture Fund I, LLC
	 	8,026            
		
	 Westly Group
	 	381,219            
		
	 Northport Investments
	 	21,207            
		
	 Orgone Capital
	 	81,274            
		
	 Innovative Financial Private Equity
	 	12,039            
		
	 Advanced Equities Amyris Investments I, LLC
	 	1,989            

 EXHIBIT D 

SCHEDULE OF SERIES C INVESTORS (cont.) 
  

			
	 SERIES C INVESTOR

	 	NUMBER OF
  SHARES OF 
SERIES  
C STOCK
		
	 Advanced Equities Amyris Investments II, LLC
	 	5,034        
		
	 Khosla Ventures III, L.P.
	 	98,661        
		
	 KPCB Holdings, Inc., as nominee
	 	98,660        
		
	 TPG Biotechnology Partners II, L.P.
	 	98,660        
		
	 Total
	 	4,902,665        

 EXHIBIT E 

SCHEDULE OF SERIES C-1 INVESTORS 
  

			
	 SERIES C-1 INVESTOR

	 	NUMBER 
OF
SHARES OF SERIES
C-1 STOCK
		
	 Maxwell (Mauritius) Pte Ltd
	 	2,724,766        
		
	 Total
	 	2,724,766        

 EXHIBIT F 

SCHEDULE OF COMMON HOLDERS 
  

			
	 NAME OF
KEY EMPLOYEE
	 	NUMBER 
OF
SHARES OF
  COMMON 
STOCK  
		
	 Jack D. Newman
	 	900,000        
		
	 K. Kinkead Reiling
	 	863,000        
		
	 Jay D. Keasling
	 	1,000,000        
		
	 Neil Renninger
	 	900,000        
		
	 John G.
Melo1
	 	1,204,979        
		
	 Total
	 	4,867,979        

 

1
 Mr. Melo has options outstanding to purchase 1,204,979 shares of common stock.Form of Warrant to Purchase Series B-1 Preferred Stock

 Exhibit 4.05 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES
LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION THEREUNDER
OR EXEMPTIONS FROM SUCH REGISTRATION REQUIREMENTS. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL
IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 

WARRANT TO PURCHASE SERIES B-1 PREFERRED STOCK 

OF 

AMYRIS BIOTECHNOLOGIES, INC. 
  

			
	Number of Shares:	  	[          ] shares
		
	Class of Stock:	  	Series B-1 Preferred Stock
		
	Initial Exercise Price:	  	$25.26 per share
		
	Issue Date:	  	[March 31,             ]/[June 30,
            ]/[September 30,             ]/[December 31,
            ]
		
	Expiration Date:	  	[March 31,             ]/[June 30,
            ]/[September 30,             ]/[December 31,
            ]

 This WARRANT (this
“Warrant”) certifies that, for good and valuable consideration, Advanced Equities Financial Corp. or its permitted registered assigns (“Holder”) is entitled to purchase from Amyris Biotechnologies,
Inc., a California corporation (the “Company”), at any time until 5:00 p.m. (Pacific Time) on the Expiration Date set forth above, the number of fully paid and nonassessable shares of the class of stock (the
“Shares”) of the Company at the Initial Exercise Price per Share (the “Warrant Price”), all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and
upon the terms and conditions set forth in this Warrant. 
  

	 	1.	 EXERCISE. 

1.1        Method of Exercise. Holder may exercise this Warrant by
delivering a duly executed Notice of Exercise in substantially the form attached as Exhibit A to the principal 

 
office of the Company. This Warrant may be exercised in whole or in part and Holder shall also deliver to the Company a check for the aggregate Warrant Price for the Shares being purchased.

 1.2        Net Exercise Election. Holder may elect to
convert this Warrant, without the payment by Holder of any additional consideration, by the surrender of this Warrant to the Company, with the net exercise election selected in the Notice of Exercise attached hereto as Exhibit A duly
executed by Holder, into the number of Shares that is obtained under the following formula: 
  

			
	X =	 	 Y  (A-B)

		 	   A

  

					
	 Where:
	    	 X =
	  	the number of Shares to be issued to Holder pursuant to this Section 1.2.
			
		    	 Y =
	  	the number of Shares then subject to this Warrant.
			
		    	 A =
	  	the fair market value of one Share, as determined in good faith by the Company’s Board of Directors, as at the time the net exercise election is made pursuant to this
Section 1.2.
			
		    	 B =
	  	the Warrant Price.

 For purposes of the
above calculation, fair market value of one Share shall be determined by the Company’s Board of Directors in good faith; provided, however, that where there exists a public market for the Company’s Common Stock at the time of such
exercise, the fair market value per share shall be the product of (i) the average of the closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary or the last reported sale price of the Common Stock or the
closing price quoted on any exchange on which the Common Stock is listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the five (5) trading days prior to the date of determination of fair
market value and (ii) the number of shares of Common Stock into which each Share is convertible, if applicable, at the time of such exercise. Notwithstanding the foregoing, in the event this Warrant is exercised in connection with the
Company’s initial public offering of Common Stock, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of
Common Stock into which each Share is convertible, if applicable, at the time of such exercise. The Company will promptly respond in writing to an inquiry by Holder as to the then current fair market value of one Share. 

1.3        Delivery of Certificate and New Warrant. Promptly after
Holder exercises this Warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, this Warrant shall automatically be reduced by the number of
Shares issued and remain exercisable for such remaining Shares not so acquired, and all other terms of the Warrant shall otherwise remain in full force and effect as so adjusted. Upon final exercise of this Warrant for any such remaining number of
Shares, this Warrant shall be surrendered by Holder to the Company for cancellation. 

1.4        Replacement of Warrants. On receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in 
  

 2 

 
the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, or surrender and
cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

1.5        Acquisition, Asset Sale, Liquidation of the Company. In
the event the Company proposes to effect (i) an Acquisition (as such term is defined in the Company’s Amended and Restated Articles of Incorporation, as amended from time to time (the “Articles of Incorporation”));
(ii) an Asset Sale (as defined in the Articles of Incorporation); or (iii) a Liquidation (as defined in the Articles of Incorporation), the Company shall give Holder at least ten (10) days advance written notice of such event (the
“Company Notice”), which notice shall include the Company’s best estimate of the value of the Shares receivable upon exercise or conversion of this Warrant and the proposed date upon which such event is expected to
occur. During such notice period, Holder may exercise this Warrant in accordance with its terms, whether or not exercise is contingent upon the happening of such event and/or existence of a minimum value of the Shares receivable upon exercise as
provided on Holder’s exercise notice. Subject to prior exercise as provided in the preceding sentence, this Warrant will terminate immediately prior to the happening or consummation of the event described in the Company Notice. 

 

	 	2.	 ADJUSTMENTS TO THE SHARES. 

2.1        Stock Dividends, Splits, Etc. If the Company declares
or pays a dividend on the outstanding shares of the Company’s Common Stock payable in shares of the Company’s Common Stock or other securities of the Company or subdivides or combines the outstanding shares of the Company’s Common
Stock, then upon exercise or conversion of this Warrant, unless, in case this Warrant is exercisable into shares of the Company’s Preferred Stock and the conversion ratio of such Preferred Stock already reflects such event for each Share
acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares of record as of the date the dividend, subdivision or combination occurred.

 2.2        Reclassification, Exchange or Substitution.
Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant (other than a merger, consolidation or recapitalization
described in Section 1.5 above or a stock dividend, split, etc. described in Section 2.1 above), Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder
would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution or other event. By way of example, such an event shall include any automatic conversion of the outstanding or
issuable securities of the Company of the same class or series as the Shares to Common Stock pursuant to the terms of the Company’s Articles of Incorporation upon the closing of a registered public offering of the Company’s Common Stock.
The Company or its successor shall promptly issue to Holder a new Warrant for such new securities or other property. The new Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided
for in this Section 2 
  

 3 

 
including, without limitation, appropriate adjustments to the Warrant Price and to the number of securities or property issuable upon exercise or conversion of the new Warrant. 

2.3        Adjustments of Warrant Price. If the outstanding Shares
are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are divided by reclassification or otherwise, into a greater number of
shares, the Warrant Price shall be proportionately decreased. 

2.4        Conversion of Warrant Stock. If all the outstanding
shares of that particular series of preferred stock defined herein as the “Shares” and specifically identified in the preamble of this Warrant (the “Series”) of the Company are converted into Common Stock pursuant
to the Company’s Articles of Incorporation (subject to the provisions of Section 1.5) or otherwise, or such Series otherwise ceases to exist, then, from and after the date on which such Series is so converted or ceases to exist (the
“Conversion Date”): (i) this Warrant will be exercisable for Common Stock of the Company and the term “Shares” (wherever used in this Warrant) will thereafter mean the Company’s Common Stock; and
(ii) the Warrant Price will be the price obtained by dividing (a) the Purchase Price in effect immediately prior to the Conversion Date by (b) the number of shares of Common Stock (including fractional shares) into which each share of
such Series was convertible immediately prior to the Conversion Date (subject to subsequent adjustment as provided herein). 

2.5        Adjustment is Cumulative. The provisions of this
Section 2 shall similarly apply to successive stock dividends, stock splits or combinations, reclassifications, exchanges, substitutions, or other events. 

2.6        Fractional Shares. No fractional Shares shall be
issuable upon exercise or conversion of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of this Warrant, the Company shall
eliminate such fractional Share interest by paying Holder an amount by check computed by multiplying the fractional interest by the fair market value of a full Share. 

2.7        Certificate as to Adjustments. Upon each adjustment of
the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is based. The Company
shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 

 

 4 

 3.      REPRESENTATIONS AND
COVENANTS OF THE COMPANY. The Company hereby represents and warrants to Holder that all Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of
the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws.

  

	 	4.	 REPRESENTATIONS AND AGREEMENTS OF HOLDER. 

4.1        Representations. Holder hereby represents and warrants
to the Company as follows. Holder is a sophisticated investor having such knowledge and experience in business and investment matters that Holder is capable of protecting Holder’s own interests in connection with the acquisition, exercise or
disposition of this Warrant. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act. Holder is aware that this Warrant and the Shares are being, or will be, issued to Holder in reliance upon
Holder’s representation in this Section 4 and that such securities are restricted securities that cannot be publicly sold except in certain prescribed situations. Holder is aware of the provisions of Rule 144 promulgated under the Act
and of the conditions under which sales may be made thereunder. Holder has received such information about the Company as Holder deems reasonable, has had the opportunity to ask questions and receive answers from the Company with respect to its
business, assets, prospects and financial condition and has verified any answers Holder has received from the Company with independent third parties to the extent Holder deems necessary. Holder, by acceptance hereof, acknowledges this Warrant and
the Shares to be issued upon exercise hereof or conversion thereof are being acquired solely for Holder’s own account and not as a nominee for any other party, and for investment, and that Holder will not offer, sell or otherwise dispose of
this Warrant or any Shares to be issued upon exercise hereof or conversion thereof except under circumstances that will not result in a violation of the Act or any state securities laws. 

4.2        Legends. This Warrant and the Shares (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 
  

					
		  	THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN
EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR LAW OR PURSUANT TO RULE 144 AND ANY STATE EXEMPTION FROM REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.	  	

 4.3        Compliance with Securities
Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part

  

 5 

 
without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and
legal opinions satisfactory to the Company, as reasonably requested by the Company). 

4.4        Transfer Procedure. Subject to the provisions of
Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company a written notice
of the portion of the Warrant being transferred, such notice setting forth the name, address and taxpayer identification number of the transferee, and surrendering this Warrant to the Company for reissuance to the transferee(s) (and to the new
Warrant Holder for any remaining Shares, if applicable); provided that this Warrant may only be transferred to an “affiliate” (within the meaning of Rule 405 of Regulation C promulgated under the Act) of Holder. 

If a transfer of all or part of this Warrant is permitted by the preceding paragraph, then this Warrant and all rights
hereunder may be transferred, in whole or in part, on the books of the Company maintained for such purpose at the principal office of the Company referred to above, by Holder hereof in person, or by duly authorized attorney, upon surrender of this
Warrant properly endorsed and upon payment of any necessary transfer tax or other governmental charge imposed upon such transfer together with a notice of assignment in the form attached as Exhibit B hereto. Upon any permitted partial
transfer, the Company will issue and deliver to Holder a new Warrant or Warrants with respect to the Shares not so transferred. Each taker and holder of this Warrant, by taking or holding the same, consents and agrees that when this Warrant shall
have been so endorsed, the person in possession of this Warrant may be treated by the Company, and all other persons dealing with this Warrant, as the absolute owner hereof for any purpose and as the person entitled to exercise the rights
represented hereby and subject to the restrictions contained herein, any notice to the contrary notwithstanding; provided, however that until a transfer of this Warrant is duly registered on the books of the Company, the Company may
treat Holder hereof as the owner of this Warrant for all purposes. 

4.5        Market Standoff. Holder agrees, in connection with the
Company’s initial public offering of the Company’s securities, upon request of the Company or the underwriters managing any underwritten offering of the Company’s securities: (i) not to sell, make any short sale of, loan, grant
any option for the purchase of, or otherwise dispose of any Shares (other than those included in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period of time (not to exceed one
hundred eighty (180) days) from the effective date of such registration as may be requested by the underwriters and (ii) to execute any agreement reflecting clause (i) above as may be requested by the underwriters at the time of the
initial public offering. The foregoing obligations shall apply only if all executive officers, directors and one-percent securityholders of the Company enter into similar agreements, it being understood that any such agreement shall not cover any
equity securities of the Company Holder acquires in the Company’s initial public offering or otherwise in the public market. Any discretionary waiver or termination of the restrictions of such agreements by the Company or the managing
underwriter shall apply to all persons subject to such agreements on a pro rata basis, based upon the number of shares held by each subject to such agreements. The foregoing obligations shall not apply to a registration

  

 6 

 
relating solely to employee benefit plans, or to a registration relating solely to a transaction pursuant to Rule 145 under the Securities Act. 

 

	 	5.	 GENERAL PROVISIONS. 

5.1        Notices. All notices required or permitted under this
Warrant shall be given in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the
recipient; if not, then on the next business day, (iii) five (5) days after deposit in the United States mail, by registered or certified mail, postage prepaid and properly addressed to the party to be notified as set forth on the
signature page hereof, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties hereto, or (iv) one (1) day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. 

5.2        Attorneys Fees. In the event of any dispute between the
parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.3        Governing Law. This Warrant will be governed by and
construed in accordance with the laws of the State of California, without giving effect to that body of laws pertaining to conflict of laws. 

5.4        Further Assurances. The parties agree to execute such
further documents and instruments and to take such further actions as may be reasonably necessary to carry out the purposes and intent of this Warrant. 

5.5        Titles and Headings. The titles, captions and headings
of this Warrant are included for ease of reference only and will be disregarded in interpreting or construing this Warrant. Unless otherwise specifically stated, all references herein to “sections” and “exhibits” will mean
“sections” and “exhibits” to this Warrant. 

5.6        Counterparts. This Warrant may be executed in any
number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. 

5.7        Severability. If any provision of this Warrant is
determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or
provision cannot be so enforced, such provision shall be stricken from this Warrant and the remainder of this Warrant shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not enforceable) never been
contained in this Warrant. Notwithstanding the forgoing, if the value of this Warrant based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding court or arbitrator of
competent jurisdiction shall be binding, then both parties agree to substitute such provision(s) through good faith negotiations. 
  

 7 

 5.8        Facsimile
Signatures. This Warrant may be executed and delivered by facsimile and upon such delivery the facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other party. The original
signature copy shall be delivered to the other party by express overnight delivery. The failure to deliver the original signature copy and/or the nonreceipt of the original signature copy shall have no effect upon the binding and enforceable nature
of this Warrant. 
 5.9        Amendment and Waivers.
This Warrant may be amended only by a written agreement executed by each of the parties hereto. No amendment of or waiver of, or modification of any obligation under this Warrant will be enforceable unless set forth in a writing signed by the party
against which enforcement is sought. Any amendment effected in accordance with this section will be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of any provision of
this Warrant shall constitute a waiver of that provision as to that or any other instance. No waiver granted under this Warrant as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein,
nor shall it constitute the waiver of any performance other than the actual performance specifically waived. 

5.10        Entire Agreement. This Warrant and the documents
referred to herein constitute the entire agreement and understanding of the parties with respect to the subject matter of this Warrant, and supersede all prior understandings and agreements, whether oral or written, between or among the parties
hereto with respect to the specific subject matter hereof. 
 [Signature Page Follows] 

 

 8 

 IN WITNESS WHEREOF, the parties hereto have executed this Warrant to
Purchase Series B-1 Preferred Stock of Amyris Biotechnologies, Inc. as of the date first written above. 
  

							
	WARRANT HOLDER:	    	COMPANY:
		
	ADVANCED EQUITIES FINANCIAL CORP.	    	AMYRIS BIOTECHNOLOGIES, INC.
				
	 By:
	  	  
	    	 By:
	 	 /s/ John Melo

				
	 Name:
	  	  
	    	 Name:
	 	 John Melo

				
	 Title:
	  	  
	    	 Title:
	 	 Chief Executive Officer

				
	 Address:
	  	  
	    	 Address:
	 	 5885 Hollis Street, Suite 100

		
	  
	    	 Emeryville, CA 94608

		
	  
	    	  

				
	 Attention to:
	  	  
	    	 Attention to:
	 	 Chief Executive Officer

				
	 Facsimile:
	  	  
	    	 Facsimile:
	 	 (510) 225-8645

[Signature Page to Warrant to Purchase Series B-1 Preferred Stock of Amyris Biotechnologies, Inc.] 

 EXHIBIT A 

NOTICE OF EXERCISE 

(TO BE SIGNED ONLY UPON EXERCISE OF WARRANT) 

1.         The
 undersigned hereby elects to purchase                      shares of the Series B-1 Preferred Stock (the “Shares”) of
Amyris Biotechnologies, Inc., a California corporation, pursuant to the terms of the attached Warrant to Purchase Series B-1 Preferred Stock with an Issue Date of [March 31,
            ]/[June 30,             ]/[September 30,
            ]/[December 31,             ] (the “Warrant”), as follows: 

(Initial applicable method:) 
  

					
	  
	  	 a.
	    	The undersigned tenders herewith payment of the total purchase price of such Shares in full, pursuant to a check or wire transfer, in the amount of
$            .
			
	  
	  	 b.
	    	This exercise or conversion              [is]
             [is not] contingent upon the closing of the Acquisition, Asset Sale or other event specified in the Company Notice to Holder in accordance with Section 1.5 of the
Warrant received by Holder on                      and              [is]
             [is not] contingent upon a sale price or fair market value for the Company’s
                     Series B-1 Preferred Stock in the Acquisition, Asset Sale or other event of no less than the lesser of
(a) $             per share or (b) the per share price set forth in the Company Notice.
			
	          
	  	 c.
	    	The undersigned hereby elects to convert the Warrant into Shares by the net exercise election pursuant to Section 1.2 of the Warrant. This conversion is exercised with respect
to all of the shares of Series B-1 Preferred Stock covered by the Warrant resulting in a net total of              Shares being issued to the undersigned.

2.         Please
 issue a certificate or certificates representing said Shares in the name of the undersigned. The undersigned represents that it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward
the resale or distribution thereof except in compliance with applicable securities laws and hereby repeats the representations and warranties of the undersigned that are set forth in Section 4.1 of the attached Warrant. 

 

			
	 Advanced Equities Financial Corp.

		
	 By:
	  	  

		
	 Name:
	  	  

		
	 Title:
	  	  

 EXHIBIT B 

FORM OF ASSIGNMENT 

FOR VALUE RECEIVED the undersigned Holder of this Warrant hereby sells, assigns and transfers unto the Assignee named
below all of the rights of the undersigned under the within Warrant, with respect to the number of shares of the Shares set forth below: 
  

					
	 Name of Assignee
	  	Address	  	No. of Shares
		  		  	
		  		  	

 and does hereby irrevocably constitute and appoint
                                         
    Attorney to make such transfer on the books of Amyris Biotechnologies, Inc., a California corporation, maintained for the purpose, with full power of substitution in the premises. 

 

									
	 Dated:
	 	  
	  		  	 Advanced Equities Financial Corp.

					
		 		  		  	By:	 	  

									
					
		 		  		  	   Name:
	 	  

									
					
		 		  		  	    Title:
	 	  

 Schedule 

of 
 Warrants to
Purchase Shares of Series B-1 Preferred Stock Issued by the Registrant to Advanced 
 Equities Financial Corp. 

on the 
 Form of
Warrant to Purchase Series B-1 Preferred Stock of the Registrant to Advanced Equities 
 Financial Corp. 

 

					
	 Issue Date
	  	 Number of Warrant Shares
	  	 Expiration Date

			
	3/31/08	  	8,991	  	3/31/15
			
	6/30/08	  	53,916	  	6/30/15
			
	9/30/08	  	32,330	  	9/30/15
			
	12/31/08	  	5,478	  	12/31/15
			
	3/31/09	  	3,843	  	3/31/16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]